Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0

The Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials, and other oncology settings. Developed by the National Cancer Institute (NCI), CTCAE provides a systematic approach to reporting and categorising the side effects associated with cancer treatments, enabling consistent communication among healthcare providers, researchers, and regulatory bodies.

CTCAE includes a comprehensive list of adverse events that can occur during cancer treatment, ranging from mild symptoms to severe complications. Each adverse event is assigned a specific grade that reflects its severity, allowing clinicians and researchers to assess the impact of therapy on patient health more effectively. This standardised framework is crucial for evaluating the safety and tolerability of new treatments, as it helps ensure that all parties involved in clinical trials use a common language when discussing adverse effects.

By facilitating the collection of adverse event data across different studies and clinical settings, CTCAE enhances the ability to identify potential patterns of toxicity, improve patient safety, and inform clinical decision-making. Furthermore, it plays a vital role in regulatory submissions, as it provides the evidence needed for the approval of new therapies by demonstrating their safety profiles.

Overall, CTCAE serves as an essential tool for the oncology community, promoting standardised practices in the monitoring and reporting of adverse events, ultimately contributing to improved patient care and outcomes in cancer therapy.